Showing 1531-1540 of 8826 results for "".
Novel PsO Drug Could Be 'Closest Perception of a Cure,' Dr. Strober Says at Maui Derm
https://reachmd.com/programs/practical-dermatology/novel-pso-drug-could-be-closest-perception-of-a-cure-dr-strober-says-at-maui-derm/32922/A novel monoclonal antibody targeting IL-23 for the treatment of psoriasis offers an extended half-life that will be a key differentiator for patients, according to Bruce Strober, MD, PhD.Dr. Anderson on New Tech That ‘Could be Revolutionary’ at Maui Derm
https://practicaldermatology.com/conferences/maui-derm-hawaii-2025/dr-anderson-on-new-tech-that-could-be-revolutionary-at-maui-derm/32921/In-vivo microscopy that will change how dermatologists practice and potentially revolutionary drug delivery systems were among the technologies highlighted by R. Rox Anderson, MD, PhD, during “Innovation in Dermatology 2025: A Look Into the Future of Dermatology” at the Maui Derm Hawaii 2025 meetingDr. Eichenfield Urges Caution for Steroid-Phobia at Maui Derm
https://practicaldermatology.com/conferences/maui-derm-hawaii-2025/dr-eichenfield-urges-caution-for-steroid-phobia-at-maui-derm/32919/In addition to the various clinical skin conditions that pediatric patients present with, dermatologists now must understand how to deal with steroid-phobia, according to Lawrence Eichenfield, MD.Journal Club: Pediatric Treatment Adherence
https://reachmd.com/programs/Practical-Dermatology-Atopic-Dermatitis-Journal-Club/journal-club-pediatric-treatment-adherence/32401/Practical Dermatology Editorial Board members Lawrence Eichenfield, MD, FAAD, Jason Hawkes, MD, MS FAAD, discuss the article "Treatment Adherence in Pediatric Atopic Dermatitis: A Systemic Review," from Pediatric Dermatology as well as their favorite strategies for treatment adherence and the impactCombining Aesthetic Treatments: Dr. Chilukuri
https://practicaldermatology.com/conferences/maui-derm-hawaii-2025/combining-aesthetic-treatments-dr-chilukuri/32692/Suneel Chilukuri, MD, talks about some of the new regenerative options and combining them with devices and other therapies, as discussed in "What's My Treatment? How to Combine Dermal Filler, Neuromodulators, Laser/Light/RF Devices/Microneedling and Cosmeceuticals Symposium" at Maui Derm 2025.Psoriasis Update 2025: Dr. Gelfand
https://practicaldermatology.com/programs/practical-dermatology/psoriasis-update-2025-dr-gelfand/32672/Joel Gelfand, MD, MSCE, discusses highlights from the "Psoriasis Update 2025" panel at Maui Derm 2025, including the potential for combining TNF inhibitors with IL-23 inhibitors; home phototherapy; and the possibility of GLP-1 agonists lowering the severity of psoriatic disease.DermwireTV 2024 Year in Review
https://practicaldermatology.com/series/dermwire-tv/dermwiretv-2024-year-in-review/32206/We look back at the top stories of 2024 in the Dermatology and Aesthetics markets. Several new products were approved or launched in atopic dermatitis, rosacea, prurigo nodularis, and hidradenitis suppurativa; new clinical guidelines were made for AD, acne care, and skin cancer; and a new study raisSDPA: Dr. Matthew Zirwas Shares Passion for Treating Atopic Dermatitis
https://practicaldermatology.com/conferences/sdpa-2024/sdpa-dr-matthew-zirwas-shares-passion-for-treating-atopic-dermatitis/29509/At the SDPA 22nd Annual Fall Dermatology Conference, Practical Dermatology caught up with Matthew Zirwas, MD. He provides a passionate overview of his lecture on atopic dermatitis, itch, and contact dermatitis.SDPA: Andrew Mastro on Advancing Career By Building Yearly Goals
https://practicaldermatology.com/conferences/sdpa-2024/sdpa-andrew-mastro-on-advancing-career-by-building-yearly-goals/29512/At the SDPA 22nd Annual Fall Dermatology Conference, Practical Dermatology caught up with Andrew Mastro, PA-C. Each year, Mastro leaves SDPA with a yearly goal in mind. He breaks down how SDPA contributes to the goal and what he does to achieve it.Get Ready for JAK Inhibitors
https://practicaldermatology.com/topics/psoriasis/get-ready-for-jak-inhibitors/19928/JAK inhibitors are going to change the way we think about refractory disease, says Brett King, MD. He addresses the significant increase in study of these agents and the many potential uses for refractory diseases like alopecia, atopic dermatitis, vitiligo, psoriasis, and more.